DALLAS, Dec. 03, 2018 (GLOBE NEWSWIRE) — via OTC PR WIRE — Puration, Inc. (USOTC: PURA) today announced that the company’s CBD Beverage Deal with Generex was a highlighted topic in today’s Generex Biotechnology Corp. (OTCQB: GNBT) shareholder conference call. The deal was discussed in both the Generex Management Presentation and discussed again in response to shareholder questions when CEO Joseph Moscato addressed the quality and caliber of the underlying extraction process utilized by Puration. Puration has the sole license for beverage production of U.S. Patent No. 9,199,960 entitled ‘METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT’. The patented is owned by Puration partner Kali, Inc. (USOTC: KALY) and Kali will assist Puration in the deal with Generex in the formulation of specific extract concentrates to address Generex defined therapies.
For more information on Puration, visit www.purationinc.com
For more information on Generex, please visit:www.Generex.com
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.